Source: Instrument Family, unauthorized reproduction is prohibited, and reprinting is allowed 24 hours later.

Recently, JWMS has made a new investment in the "Innovation and Industrialization Project of Next-Generation Drug-Device Combination Interventional Medical Devices."Additional registered capital of 30 million US dollars (approximately 200 million RMB). On June 23, the additional registered capital of 30 million US dollars was fully in place.

Data shows that JWMS is an important entity company of Blue Sail Medical's cardiovascular and cerebrovascular division, with over 20 years of industry experience in the coronary intervention field.This capital increase also indicates that Bluestar Healthcare is doubling down on the cardiovascular track.

It is worth mentioning that, in mid-June,Blue Sail Medical Science and Technology Innovation Headquarters and Industrialization Base Project Officially Breaks Ground in Zhangjiang International Medical Park, Pudong, Shanghai.According to reports, after the completion of this project, it will become Blue Sail Medical's global innovation and R&D headquarters base, investment incubation platform, high-end medical device production, as well as the global commercial headquarters.

As a company with a complete layout in both low-to-mid-value consumables and high-value consumables,Blue Sail Medical is known in the industry as the "hidden champion of low-cost consumables."At the outbreak of the COVID-19 pandemic, it became an industry leader with medical gloves as the core of its medical protective products.But with the stabilization of global pandemic prevention and control, some industry insiders believe that: For Blue Sail Medical to achieve long-term development in the industry, it must seek new growth points.

01

Blue Sail Medical Increases Investment by 200 Million

Double Down on Cardiovascular Track

It is reported that JWMS was in line with the direction advocated by Shandong in recent years, which is "adhering to the leading development direction of high-tech industries and introducing a number of leading high-quality projects."Cultivated two billion-dollar industrial clusters in electronic information and biomedicine, and newly received a capital increase from the parent company for the research and development of new coronary technologies and products, which have been centrally signed.

On June 23, the additional registered capital of 30 million US dollars for JWMS was fully in place.

Data shows,JWMS is an important entity company of Bluestar Cardio-Cerebrovascular Division, mainly focusing on the R&D, production, and sales of high-tech interventional medical products.With over 20 years of industry experience in the coronary intervention field, its first marketed coronary stent product won the Second Prize of the National Technology Invention Award.

In 2021,Coronary stents enter the national procurement in China, and JWMS ranked first in the national coronary stent procurement.In the first year of the 2021 JWMS procurement, the total annual sales reached 450,000 units, with a market share of approximately 22% in China, ranking second nationwide.In addition, JWMS's drug-coated balloon product applied for and obtained the NMPA Innovation Channel in 2021.

02

Continuously Enriching the Cardiovascular and Cerebrovascular Product Line

High-value medical consumables sector enters harvest period

August 2021,The Beauty Mos Coating Coronary Artery Balloon Dilation Catheter developed by JWMS,Approved by the National Medical Products Administration's special review process for innovative medical devices,This is the only moses-class drug balloon product applicable to small vessel lesions in the Chinese market.

This drug-coated balloon utilizes the company's exclusive patented drug, BA9.With 10 times higher lipophilicity than ordinary rapamycin, it can reduce drug loss during delivery., accelerates drug absorption at the lesion site and has a tissue half-life of up to 20 days, making it the preferred choice for coating drugs.

In fact, since 2021,JWMS continues to invest heavily in the coronary intervention field, with five new coronary products launched in China, including three new balloon products and two new stent products.Among them, two domestically produced balloon models have been awarded bids in the coronary artery expansion balloon procurement projects of some provinces in China.

In recent years, the medical device market in China has developed rapidly,Blue Sail Medical has formulated a development strategy to use coronary intervention business as a fulcrum and continuously enrich and expand the medical device product line in the cardiovascular and cerebrovascular fields.Firmly optimistic about the fields of coronary, structural heart disease, neurology, and peripheral interventions.

Changyuan® Intracranial Balloon Dilatation Catheter

Last month,The first neurointerventional product from Blue Sail Medical has been approved for marketing in China.Reportedly, the newly approved product is named Changyuan® Intracranial Balloon Dilation Catheter. This product features the smallest specifications of intracranial balloon (1.0mm diameter, 5mm length), the longest working segment (40mm), a small distal outer diameter, and a multi-stage tapered delivery system, allowing it to easily reach the lesion site and complete the dilation.Excellent performance in treating distal intracranial artery stenosis, with 71 specifications and models to fully meet clinical needs.

Approval of New Products,It also means that the high-value medical consumables segment constructed by Bluestar Healthcare, consisting of four tracks—coronary, structural heart disease, neurointervention, and peripheral intervention—has begun to enterHarvest Period.

03

Science and Technology Innovation Headquarters and Industrialization Base Project

Officially Started Construction in Zhangjiang International Medical Park

After the COVID-19 pandemic, when mentioning Blue Sail Medical, the industry first thinks of its medical protection business. However, Blue Sail Medical is not limited to its medical protection business centered on medical gloves.

In June this year,Blue Sail Medical Science and Technology Innovation Headquarters and Industrialization Base Project Officially Breaks Ground in Zhangjiang International Medical Park, Pudong, Shanghai.

It is reported that the Blue Sail Medical Science and Innovation Headquarters and Industrialization Base project is located in the International Medical Park of Zhangjiang Science City, Pudong. The construction period will last for 3 years, covering a total area of 43.6 mu, with a total building area of 150,000 square meters, and the main building will be up to 15 stories high. Notably,In the design of this project, the company emphasized the functions of research and development, industrialization, and incubation, and the overall construction proportion of these functions will reach 70%.

It is reported that theAfter the completion of the project, it will become the company's global innovation and R&D headquarters base, investment incubation platform, high-end medical device production, and global commercial headquarters.

Renderings of Blue Sail Medical Project

At the same time, relying on Shanghai's advantages of talent aggregation, rich interdisciplinary resources, and high internationalization, this project will create a platform for innovative R&D, a platform for incubating new businesses and models, a platform for open cooperation, and a platform for resource aggregation and symbiosis.By continuously incubating leading innovative technologies through self-research, investment, and equity participation, Blue Sail Medical pushes its technology to the forefront globally.

Liu Wenjing, Chairman of Blue Sail Medical, once said:"We will fully leverage our core values of openness and altruism,Not only to build itself as a new engine and connector for multi-level innovative R&D both internationally and within China, but also to open up to the outside, gathering and coexisting with various partners in the industry, acting as a connector and amplifier for collaborative innovation and development.”

04

Cardio-cerebrovascular Business is Expanding

May become a new direction for business growth

In 2020, due to the outbreak of COVID-19, orders for medical protective equipment, nucleic acid test kits, ECMO, and other medical devices surged globally. Their selling prices rose significantly, and some medical devices were continuously out of stock.

With medical gloves as the core of medical protective products,Blue Sail Medical Becomes an Industry Leader. In 2020, Blue Sail Medical achieved a revenue of 7.869 billion yuan, representing a year-on-year increase of 126.42%. By 2021, Blue Sail Medical's revenue reached 8.109 billion yuan, marking a year-on-year growth of 3.04%.Compared with 2020, its business has entered a stable development period. An industry insider thus proposed:For Blue Sail Medical to achieve long-term development in the industry, it must seek new growth points.

Public information shows that Blue Sail Medical is a leading medical device company with a complete layout in both low-value and high-value consumables. Its four major divisions are the Protection Division, Cardio-Cerebrovascular Division, Surgical Division, and Nursing Division.In 2021, the revenue of Blue Sail Medical's cardiovascular and cerebrovascular products was 709 million yuan, accounting for 8.75% of the total revenue.. Although this data is much smaller compared to the revenue of core health protection products, it also indicates,Blue Sail Medical is expanding into other fields beyond protective products.

Screenshot from Blausen Medical's 2021 annual report

It is reported that currently, Bluestar Medical mainly engages in the research, production, and sales of cardiac stents and interventional cardiac surgery-related device products.The main products include drug-eluting stents, drug-coated stents, balloon catheters, implantable devices for transcatheter aortic valve replacement (TAVR), and various other配套 products for interventional cardiac surgeries.

Currently, Drug-Coated Balloons (DCB) are undergoing clinical trials, and the new generation of TAVR products is planned to conduct clinical trials in Europe, Southeast Asia, and China in 2022.The products under development also include solutions for full calcified lesions/CTO lesions in coronary arteries, transcatheter mitral valve repair and replacement, and several other projects.

Coronary Stent

In June 2021, the world's first non-coated drug stent developed by Bluestar HealthcareBioFreedom™ Approval for registration in China,This product is the world's first stent that can reduce the postoperative dual antiplatelet therapy duration from 1 year to 1 month.Fundamentally preventing the risk of bleeding in patients, it has become the only imported drug-eluting stent approved by the China Food and Drug Administration for 1-month DAPT in high-bleeding-risk patients.

As of December 2021, the BioFreedom™ product has been listed in more than half of the provinces in China.AndSales have been achieved in 28 European and South American countries, including Spain, Italy, France, the United Kingdom, Chile, the Czech Republic, Austria, and Germany, gaining high recognition in these markets.

COVID-19 Related Interventional Balloon

Blue Sail Medical's interventional cardiology products also include drug-coated balloon catheters, balloon dilation catheters, as well as proprietary or distributed catheters, guidewires, and other related devices for interventional cardiac surgeries.Core products include drug-coated balloon catheters, PTCA coronary balloon catheters (BioStream™), and balloon dilation catheters (Powerline™, RISE™ NC).

June 2021,RISE™ NC Balloon Dilatation Catheter Produced by Biosensors Europe SA Obtains Medical Device Registration Certificate Approved by the National Medical Products Administration (NMPA),Further enriches the company's cardiovascular intervention product portfolio in mainland China.

In August 2021, the Umirolimus Coated Coronary Balloon Dilatation Catheter developed by JWMS, a subsidiary of Shandong Jiwei Medical Products Co., Ltd., received approval under the National Medical Products Administration's special review procedure for innovative medical devices.This is also the only mophine-class drug balloon product applicable to small vessel disease in the Chinese market.

Structural Heart Disease Interventional Valve Products

Currently,NVT, a company acquired cross-border by Blue Sail Medical, has three generations of products in the aortic valve field. Its first-generation product, Allegra™, obtained EU CE certification in March 2017.Approved for the "valve-in-valve" indication in Europe in 2020, the first-generation product once again demonstrated its excellent safety with a very low mortality rate of 1.2% based on real-world multicenter short-term clinical results.The second-generation product is planned to conduct clinical trials simultaneously in Europe and China in 2022; the third-generation product is scheduled to initiate clinical trials in Europe and China in 2023.

Allegra™ TAVR System

At the same time, Bluestar Healthcare has begun to develop product reserves for the next generation of aortic valve technology.As well as the preliminary research work on products in the fields of mitral valve and tricuspid valve repair and replacement.

——

Public information shows that Bluestar Healthcare was established in 2002,A leading medical device enterprise with a comprehensive layout of medium-low value consumables and high-value consumables.The company's four major sectors are: medical gloves as the coreProtective Products Division,Centered on the cardiac stentCardiovascular Division,Centered on staplers and ultrasonic scalpelsSurgical DivisionAnd with the first aid kit as the coreNursing Division.

In 2021, to optimize the company's overall business framework,Blue Sail Medical undergoes internal restructuring of all subsidiaries and business entities within the cardiovascular and cerebrovascular division.Fully integrate the coronary business and structural heart disease business in terms of equity structure and management structure.

Blue Sail Medical previously stated that the company will continue to adhere to a combination of investment mergers and acquisitions with innovative research and development.Continuously develop and acquire new products with core technologies and adapt to market demands, and accelerate the coordination and layout of the cardiovascular and cerebrovascular sector.And relying on a global R&D platform, in multiple high-value consumable fields such as coronary, valve, neuro-intervention, and peripheral intervention, the company is conducting innovative R&D on dozens of significant new products, becoming a new engine for the company's future sustainable development.

Unlike other companies that saw a surge in performance due to the COVID-19 pandemic,Blue Sail Medical has been seeking new market opportunities and diversifying its layout, which has become an important measure for Blue Sail Medical to capture market share.In the post-pandemic volatile market environment, multi-pronged strategies will give Blue Sail more confidence to embrace changes.

So, Lanfan Medical, which competes on the same stage as cardiovascular giants like Abbott, Boston Scientific, and Medtronic,What kind of development will the future bring after the continuous strengthening of the layout in the cardiovascular field?In this regard, the Medical Device Family will continue to pay attention.

Increased Investment of 200 Million Yuan: "Low-Consumption Invisible Champion" Expands into This High-Consumption Track